Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine

Competing Interest Statement

S. L. H. is an employee of Sanaria (Rockville, Maryland), which manufactures the PfSPZ Vaccine and is a named inventor on patents related to this vaccine.

Clinical Trial

NCT02687373

Funding Statement

This work was supported by the Doris Duke Charitable Foundation Clinical Scientist Development Award (Grant #2018091 to TMT) and the National Institutes of Health Vaccine Research Center. Grant #2018091 was not used to carry out the mouse experiments in this study. TMT was also supported by supported by grant K08AI125682 (National Institute of Allergy and Infectious Diseases). In vivo mouse experiments were supported by Indiana University Health—Indiana University School of Medicine Strategic Research Initiative (NWS). The Indiana University Melvin and Bren Simon Cancer Center Flow Cytometry Resource Facility is funded in part by NIH, National Cancer Institute grant P30 CA082709, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant U54 DK106846, and by NIH instrumentation grant 1S10D012270. Sequencing experiments for the KSPZV1 samples were carried out in the Center for Medical Genomics at Indiana University School of Medicine, which is partially supported by the Indiana University Precision Health Initiative.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics statement. Written informed consent was obtained from a parent/guardian of each infant. The clinical study protocol was approved by institutional review boards (IRB) of the Kenya Medical Research Institute (KEMRI), the US-based Centers for Disease Control and Prevention (CDC), the Kenya Pharmacy and Poisons Board (PPB) and was registered at ClinicalTrials.gov (NCT02687373). The laboratory study protocol for secondary use of de-identified human samples, including RNA sequencing, was approved by the Indiana University IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes